ライフサイエンスコーパス: mature teratoma

1 resection of viable disease (GCT other than mature teratoma).

2 est and intrinsic chemotherapy resistance of mature teratomas.

3 1.34 [mean +/- SD]) was higher than that of mature teratoma (1.38 +/- 0.71) and necrosis or scar (1.

4 ely concordant allelic loss patterns between mature teratoma and all of the other germ cell tumor com

5 y analysis, we investigated the clonality of mature teratoma and its relationship to other components

6 the kinetic rate constants K1 and K between mature teratoma and necrosis or scar as follows: K1, 0.1

7 sac tumors, five immature teratomas, and one mature teratoma, and the remaining samples were mixed ge

8 All 16 patients had mature teratoma as one component of their mixed germ cel

9 was observed in patients who had NSGCT with mature teratoma compared with those with either NSGCT wi

10 Immature or mature teratoma compartments decreased DNAm age by 9.44

11 al interpretation nor SUVlean differentiated mature teratoma from necrosis or scar, there were statis

12 th 85% embryonal, 10% yolk sac tumor, and 5% mature teratoma histologies.

13 PC-RPLND pathology revealed mature teratoma in 178 patients (85%), immature teratoma

14 l tissue, with only necrosis found in 10 and mature teratoma in one.

15 hat the stromal cells adjacent to metastatic mature teratoma in postchemotherapy lymph node specimens

16 teratoma of the ovary (six mature) and one a mature teratoma in the mediastinum; five of five tumors

17 The presence of teratoma, particularly mature teratoma, in an NSGCT primary tumor is associated

18 Metastatic mature teratoma is often present in postchemotherapy sur

19 Malignant transformation of mature teratomas may be predicted by preoperative squamo

20 nd risk factors for relapse of children with mature teratoma (MT) and immature teratoma (IT) to assis

21 neoplastic cysts (n = 5; two endometriomas); mature teratoma (n = 3); hydrosalpinx (n = 2); fibroma (

22 could easily be differentiated visually from mature teratoma (n = 6) and necrosis or scar (n = 10).

23 onents were seen in 10 of 14 tumors in which mature teratoma showed loss of heterozygosity.

24 Fourteen of 16 mature teratomas showed allelic loss in at least one of

25 The frequency of allelic loss in mature teratoma was 50% (7 of 14) with D1S508, 33% (5 of

26 toneal lymph nodes that contained metastatic mature teratoma with "fibrosis" to determine the reactiv

27 Our data support the common clonal origin of mature teratoma with other components of malignant mixed